President Trump signed an executive order on Saturday that could change the trajectory of thousands of lives. Standing in the Oval Office alongside conservative podcaster Joe Rogan and decorated Navy SEAL Marcus Luttrell — whose 2005 survival in Afghanistan became the basis of Lone Survivor — Trump declared the order would “ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life.” The directive instructs the FDA Commissioner to fast-track priority review of psychedelic therapies that have received Breakthrough Therapy designations, commits $50 million in federal match funding to states building ibogaine research programs, clears the way for the first-ever clinical trials of ibogaine on U.S. soil, and expands patient access through Trump’s own Right to Try framework. Ibogaine stays on Schedule I for now. But the runway for relief has never been wider.
This is not experimental sentimentality. This is overdue policy applied to a crisis Washington has let fester for decades.
For years the FDA treated ibogaine as though it were synthesized in a rogue chemistry lab rather than extracted from a plant whose healing applications span centuries. Veterans carrying PTSD and traumatic brain injuries have quietly flown to unregulated clinics in Mexico for treatment American doctors cannot legally provide at home. My brother is a retired Special Forces Green Beret. Several of his close friends, men who look like your neighbors coaching Little League on a Saturday morning, carry wounds that refuse to stay quiet. Last year I attended a fundraiser for psychedelic treatments in Coronado, headlined by former Texas Governor Rick Perry, alongside a retired SEAL buddy who has fought severe PTSD for years. Whatever tools might give men like him their footing back, we should pursue without apology. These are not people chasing a chemical escape. They answered the call of duty.
Former Navy SEAL and podcast host Shawn Ryan has spoken openly about his own ibogaine experience and backed federal legislation for clinical trials. One account he shared involved a retired Green Beret who arrived for treatment unable to walk without a cane most days of the week. He left without it, his symptoms lifted. He reconnected with his family in ways he had stopped believing were possible. That story tracks with what my brother’s network has described for years, account after account.
The Stanford data gives those stories a clinical foundation. A January 2024 study published in Nature Medicine by researchers at the Stanford Brain Stimulation Lab enrolled 30 U.S. Special Operations veterans with traumatic brain injuries. Each received a supervised dose of ibogaine combined with magnesium to reduce cardiac risk. One month later, PTSD symptoms had fallen 88%, depression 87%, and anxiety 81% against pre-treatment baselines. Disability ratings collapsed from a score reflecting mild to moderate impairment to one equivalent to no disability at all. No unexpected serious adverse events were recorded. These were combat-hardened Americans whose brains had absorbed blast waves across multiple deployments. Lead researcher Dr. Nolan Williams called the results “dramatic” and stated that “no other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury.”
The urgency is not academic. According to the VA’s most recent annual report, 17.5 veterans died by suicide every day in 2023 — a rate of 35.2 per 100,000, up from 34.7 the prior year. The pills and protocols that work for some leave too many others staring at the ceiling at 3 a.m. Ibogaine is not a universal answer. It is a serious alternative for the substantial population that has already exhausted conventional treatment.
Former Texas Governor Rick Perry understood that early. After witnessing ibogaine’s effect on veterans in his own circle, he co-founded Americans for Ibogaine and became the public face of the bipartisan push to accelerate research. Texas followed through in June 2025 when Governor Greg Abbott signed SB 2308 into law, allocating $50 million — the largest state-funded psychedelic research investment in U.S. history — to support ibogaine clinical trials. The federal executive order signed today is designed to amplify that momentum, with ARPA-H providing match funding to states building similar programs. FDA Commissioner Marty Makary simultaneously announced that ibogaine has received investigational new drug clearance, meaning human trials on American soil can begin for the first time.
Critics will raise the safety record, ibogaine has been linked to more than 30 deaths in the medical literature, primarily from cardiac arrhythmia in patients who were not properly screened. That concern is legitimate. Every serious treatment carries risk. The Stanford trial recorded zero serious adverse events under medical supervision, including cardiac monitoring and magnesium as a protective agent. The status quo, where veterans self-finance treatment at unregulated facilities abroad, is measurably more dangerous than a controlled clinical protocol. Arguing for the status quo on safety grounds is an argument for a system we know keeps failing the people we claim to honor.
This executive order fits the Trump template: cut the bureaucratic drag, stand with the troops, and let evidence drive. It does not claim to solve every mental health challenge facing the military. No single policy step could. What it refuses to accept is another generation of veterans managed rather than healed. Texas showed the way. Congress should clear the remaining statutory barriers once controlled trial data confirm what early research already suggests.
Our veterans earned every tool that might restore their peace. They did not serve so Washington could lecture them about caution while they inventory the ceiling at 3 a.m. President Trump just told the FDA to step aside and let doctors do their jobs. For once the federal government acted as though it answers to the people who defended it.
Jay Rogers is President of Alpha Strategies and a financial professional with more than 30 years of experience in private equity, private credit, hedge funds, and wealth management. He has a BS from Northeastern University and has completed postgraduate studies at UCLA, UPENN, and Harvard. He writes about issues in finance, constitutional law, national security, human nature, and public policy.